Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

Clinical Trials

A series of images depicting computed tomography (CT) scans of prostate cancer.

Clinical trial aims to reduce hormone therapy side effects for people with prostate cancer

A team at CCR is investigating a new device to deliver hormone therapy directly into prostate cancer tumors. The approach could improve patient quality of life by reducing burdensome side effects of current hormone therapies.

First-in-human clinical trial evaluates drug for pancreatic cancer and other solid tumors

Christine Alewine, M.D., Ph.D., a Lasker Clinical Research Scholar in the Laboratory of Molecular Biology, is leading CCR participation in a first-in-human trial to evaluate a drug for therapy of pancreatic cancer and other solid tumors. The drug aims to attack a physical barrier that helps to hide the tumor from the body’s immune system.

Steven Pavletic named Top Ten Clinical Research Achievement awardee

Steven Z. Pavletic, M.D., M.S., Senior Clinician in the Immune Deficiency Cellular Therapy Program, has been named a Top Ten Clinical Research Achievement awardee by the Clinical Research Forum for his study “A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.”

Clinical trial studies combination therapy for relapsed/refractory B-cell lymphomas

Burkitt lymphoma and diffuse large B-cell lymphoma are fast-growing cancers, and new therapies are needed for adults whose disease is not effectively treated with chemotherapy alone. Investigators at CCR are studying a combination therapy as a potential treatment for people with these aggressive cancers.

Living with and learning about neuroendocrine tumors: A conversation with Dr. Jaydira Del Rivero

Jaydira Del Rivero, M.D., Assistant Research Physician in the Developmental Therapeutics Branch, studies neuroendocrine tumors – a rare group of malignant neoplasms that originates from neuroendocrine cells and affects almost any part of the body. In this Q&A, Dr. Del Rivero and a natural history trial participant discuss an ongoing neuroendocrine study and their experiences at NIH.

Clinical trial evaluates drug for treatment of neurofibromatosis type 1 and atypical neurofibromas

Up to half of the people with neurofibromatosis type 1 develop plexiform neurofibromas (PNs), tumors that grow along nerves. Over time, PNs may transform into atypical neurofibromas (ANFs) and then into cancerous tumors. Andrea Gross, M.D., Assistant Research Physician in the Pediatric Oncology Branch, is leading a study of a drug, abemaciclib, to treat ANFs in children.

Clinical trial compares interval dosing of two immune checkpoint inhibitors

William D. Figg Sr., Pharm.D., Deputy Chief of the Genitourinary Malignancies Branch, is leading CCR’s efforts in a multi-institution, international study comparing methods of dosing nivolumab and pembrolizumab. This study is intended for people who have advanced or metastatic cancer that has not been previously treated with an immune checkpoint inhibitor.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

All about the drive: A rare kidney cancer meets its match at NIH

On New Year’s Eve, 2020, Katie Coleman was diagnosed with a very rare form of advanced kidney cancer. She enrolled in a clinical trial led by a collaborative CCR team that gave her the opportunity to have surgery in hopes of removing her tumors.

Clinical trial researches drug combination with immunotherapy for mesothelioma

Mesothelioma is a rare, fast-growing cancer that forms in membranes that surround and protect the heart, lungs and abdomen. The cells of malignant mesothelioma express large amounts of mesothelin, a cancerous protein. Investigators are researching a mesothelin-targeting drug in combination with immunotherapy.

Breadcrumb

Clinical Trials